Browsing Tag
pemvidutide
2 posts
Altimmune’s $535m balance sheet backs new pemvidutide alcohol use disorder pathway
Pemvidutide reduced heavy drinking in Phase 2, opening a new market for Altimmune as investors weigh cash, dilution and Phase 3 risks.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.